Changing the course of cancer treatment for more than 40 years
At Amgen, we are committed to the relentless pursuit of breakthroughs for cancer patients and their families. We have a deep and diverse pipeline of cutting-edge therapeutic approaches that aim to improve outcomes.
Amgen has been pursuing novel treatment approaches for more than 40 years.
We never stop looking toward the next frontier of innovation to bring the greatest potential benefit to patients.
Despite many remarkable advancements, more than 9 million lives will be lost globally to cancer this year.1
We are dedicated to delivering promising new therapies to patients with complex cancers, where there remains significant unmet need to improve outcomes. Our portfolio features many first-in-class oncology/hematology medicines and innovative therapies for recurring or difficult-to-treat cancers.
By harnessing the power of the immune system, leveraging deep knowledge of the human and cancer genome, and exploring revolutionary biomarkers, we are driving innovation in cancer treatment.
Our industry-leading oncology pipeline has greater than 20 investigational assets, across multiple targets, in more than a dozen tumor types.
We are proud to focus our research on difficult targets such as KRASG12C and to further explore our BiTE® technology.
We want to revolutionize the way cancer patients are diagnosed, treated, and cared for. We are embracing precision medicine by leveraging biomarkers and exploring targeted approaches.
Through adaptive trial design and surrogate endpoints like minimal residual disease (MRD), we can redefine measures of success and bring treatments to patients faster.2-4
DRIVING HEALTH SYSTEM
We’re bringing our expertise in biologics and manufacturing to biosimilars, because we believe meaningful savings and long-term sustainability are derived from a marketplace that encourages competition.
Our goal is to deliver high-quality, reliably supplied, and cost-saving biosimilar medicines to provide more treatment options for patients and create a more sustainable healthcare system.
With 4 approved biosimilars, including 2 oncology biosimilars on the market and with additional oncology biosimilars in development, we’re fully committed to the long-term success of biosimilars.
BiTE: Bispecific T-cell Engager; KRAS: Kirsten rat sarcoma.
1. American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society; 2019. 2. Hoelzer D. Haematologica. 2015;100(7):855-858. 3. Berry DA, Zhou S, Higley H, et al. JAMA Oncol. 2017;3(7):e170580. doi:10.1001/jamaoncol.2017.0580. 4. Harousseau JL, Avet-Loiseau H. J Clin Oncol. 2017;35(25):2863-2865.